Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1283 and mRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age
NCT07266558Phase 4Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of elasomeran, mRNA-1283.251 in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Started Nov 2025; status: active, not recruiting.
02
Drugs
elasomeranmRNA-1283.251
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07266558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266558.